SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-167346
Filing Date
2023-06-15
Accepted
2023-06-15 06:37:00
Documents
12
Period of Report
2023-06-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d525061d8k.htm   iXBRL 8-K 36724
  Complete submission text file 0001193125-23-167346.txt   166416

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20230614.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20230614_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20230614_pre.xml EX-101.PRE 11708
6 EXTRACTED XBRL INSTANCE DOCUMENT d525061d8k_htm.xml XML 3469
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 231015915
SIC: 2834 Pharmaceutical Preparations